Eupraxia Pharmaceuticals Inc. (OTCMKTS:EPRXF – Get Free Report)’s share price dropped 0.1% during trading on Tuesday . The stock traded as low as C$8.94 and last traded at C$9.00. Approximately 71,934 shares were traded during mid-day trading, an increase of 871% from the average daily volume of 7,410 shares. The stock had previously closed at C$9.01.
Eupraxia Pharmaceuticals Trading Down 0.1%
The company has a 50-day moving average of C$7.09 and a 200-day moving average of C$6.12.
Eupraxia Pharmaceuticals Company Profile
Eupraxia Pharmaceuticals, Inc (OTCMKTS:EPRXF) is a clinical-stage biotechnology company advancing adeno-associated virus (AAV)-based gene therapies for rare inherited metabolic disorders. The firm’s research platform focuses on developing single-administration treatments designed to address the underlying genetic causes of enzyme deficiencies. Eupraxia’s approach leverages targeted gene delivery to restore or supplement critical metabolic functions in patients with life-threatening conditions.
The company’s lead pipeline candidates include EPRX-101 for Ornithine Transcarbamylase (OTC) deficiency and EPRX-102 for methylmalonic acidemia (MMA), both of which are in preclinical or IND-enabling stages.
See Also
- Five stocks we like better than Eupraxia Pharmaceuticals
- America’s Next Power Move Starts Underground
- Your Signature Is Missing – Act Before It’s Too Late
- URGENT: Trump Just Triggered AI’s Biggest Disruption Yet
- NEW LAW: Congress Approves Setup For Digital Dollar?
- The biggest scam in the history of gold markets is unwinding
Receive News & Ratings for Eupraxia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eupraxia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
